Alkaloid Composition and Antiarrhythmic Activity of the Extracts from Rauvolfia serpentina Tissue Culture
Planta Medica · 2025-10 · 91 (12) · 645-655
DOI: 10.1055/a-2629-0226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Planta Medica, online erschienen am 09.07.2025. Verfasst von Aleksandr Khromov und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Institution "Institute of Pharmacology and Toxicology of the National Academy of Medical Sciences of Ukraine", Kyiv, Ukraine. Hauptthemen laut MEDLINE: Rauwolfia, Plant Extracts, Anti-Arrhythmia Agents, Indole Alkaloids. Die Arbeit nennt 27 Literaturangaben. Gefördert von: National Research Foundation of Ukraine, Simons Foundation Support Grant.
Abstract (Originalsprache)
Rauvolfia serpentina produces a number of indole alkaloids and has long been used in the traditional treatment of arrhythmia. Given the shortage of natural resources, the K-27M strain of R. serpentina tissue culture was established. The aim was to evaluate the antiarrhythmic activity of extracts with different compositions and ratios of indole alkaloids derived from the cell biomass of the K-27M strain. Chemical analysis was conducted using HPLC-MS. Adrenaline-induced (rats) and ischemia-reperfusion arrhythmia (isolated guinea pig hearts) models were used to study the antiarrhythmic activity of the extracts. Extracts were obtained from dry (extracts 1, 2, and 3) and fresh biomass (fractions 1 and 2 of extract 4). Extract 1 contained ajmaline and acetylajmaline (the total indole alkaloid content (TIAC) was 2.2% of the dry biomass); extract 2–ajmaline, acetylajmaline, and raucaffricine (TIAC 6.4%); extract 3–ajmaline and raucaffricine (TIAC 29.0%). Fraction 1 of extract 4 was dominated by vomilenine, methylajmalicine, ajmalicine, and raufloridine (TIAC 65.0%), and fraction 2 of extract 4 contained acetylajmaline (TIAC 47.4%). Extracts 1 and 2 containing negligible amounts of indole alkaloids showed a weak proarrhythmic effect. Fractions 1 and 2 of extract 4 had a pronounced antiarrhythmic effect in the adrenaline-induced arrhythmia model. In addition, fraction 2 of extract 4 had an antiarrhythmic effect in the ischemia-reperfusion arrhythmia model. The level of this activity depended on the composition and ratio of alkaloids in the extract. Thus, the K-27M strain of R. serpentina tissue culture is a promising source of indole alkaloids with antiarrhythmic activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Institution "Institute of Pharmacology and Toxicology of the National Academy of Medical Sciences of Ukraine", Kyiv, Ukraine.
- Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine, Kyiv, Ukraine.
- Scientific Service Company "OTAVA" LLC, Kyiv, Ukraine.
ORCID-Profile: Aleksandr Khromov, Natalia Dobrelia, Iryna Konvalyuk, Oleksandr Bieda, Igor Andreev, Ludmyla Mozhylevska, Sergiy Yarmoluk, Anatoliy Soloviev, Viktor Kunakh
Förderung
- National Research Foundation of Ukraine
- Simons Foundation Support Grant
Zitieren
APA
Khromov, A., Dobrelia, N., Konvalyuk, I., Bieda, O., Andreev, I., Mozhylevska, L., Yarmoluk, S., Soloviev, A., & Kunakh, V. (2025). Alkaloid Composition and Antiarrhythmic Activity of the Extracts from Rauvolfia serpentina Tissue Culture. Planta Medica, 91(12), 645-655. https://doi.org/10.1055/a-2629-0226
Vancouver
Khromov A, Dobrelia N, Konvalyuk I, Bieda O, Andreev I, Mozhylevska L, et al. Alkaloid Composition and Antiarrhythmic Activity of the Extracts from Rauvolfia serpentina Tissue Culture. Planta Medica. 2025;91(12):645-655. doi:10.1055/a-2629-0226
BibTeX
@article{Khromov2025,
author = {Khromov, Aleksandr and Dobrelia, Natalia and Konvalyuk, Iryna and Bieda, Oleksandr and Andreev, Igor and Mozhylevska, Ludmyla and Yarmoluk, Sergiy and Soloviev, Anatoliy and Kunakh, Viktor},
title = {Alkaloid Composition and Antiarrhythmic Activity of the Extracts from Rauvolfia serpentina Tissue Culture},
journal = {Planta Medica},
year = {2025},
volume = {91},
number = {12},
pages = {645--655},
doi = {10.1055/a-2629-0226}
}
EUVIMED